Analytical characteristics and comparative evaluation of Aptima HIV-1 Quant Dx assay with Ampliprep/COBAS TaqMan HIV-1 test v2.0

[1]  C. T. Nugent,et al.  Aptima HIV-1 Quant Dx--A fully automated assay for both diagnosis and quantification of HIV-1. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[2]  A. Speicher,et al.  Comparative evaluation of the Aptima HIV-1 Quant Dx assay and COBAS TaqMan HIV-1 v2.0 assay using the Roche High Pure System for the quantification of HIV-1 RNA in plasma , 2016, Clinical chemistry and laboratory medicine.

[3]  A. Caliendo,et al.  Evaluation of Performance Characteristics of the Aptima HIV-1 Quant Dx Assay for Detection and Quantitation of Human Immunodeficiency Virus Type 1 in Plasma and Cervicovaginal Lavage Samples , 2016, Journal of Clinical Microbiology.

[4]  J. Lundgren,et al.  Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV‐positive persons , 2016, HIV medicine.

[5]  Orna Mor,et al.  Evaluation of the RealTime HIV-1, Xpert HIV-1, and Aptima HIV-1 Quant Dx Assays in Comparison to the NucliSens EasyQ HIV-1 v2.0 Assay for Quantification of HIV-1 Viral Load , 2015, Journal of Clinical Microbiology.

[6]  A. Geretti,et al.  Comparative performance of the new Aptima HIV-1 Quant Dx assay with three commercial PCR-based HIV-1 RNA quantitation assays. , 2015, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[7]  S. O'shea,et al.  Performance of the Aptima® HIV-1 Quant Dx Assay on the Panther System , 2015 .

[8]  C. Delaugerre,et al.  Analytical sensitivity of three real-time PCR assays for measuring subtype B HIV-1 RNA. , 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[9]  C. Stager,et al.  COBAS ® AmpliPrep/COBAS ® TaqMan ® HIV-1 Test, Version 2.0 , 2012 .

[10]  J. González-Alba,et al.  [Quantification of HIV-1 viral load]. , 2011, Enfermedades infecciosas y microbiologia clinica.

[11]  A. Hatzakis,et al.  Comparative evaluation of the performance of the Abbott RealTime HIV-1 assay for measurement of HIV-1 plasma viral load on genetically diverse samples from Greece , 2011, Virology Journal.

[12]  R. Schall,et al.  Comparative Evaluation of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Version 2 Test Using the TaqMan 48 Analyzer and the Abbott RealTime HIV-1 Assay , 2010, Journal of Clinical Microbiology.

[13]  M. Parker,et al.  Performance of the Aptima HIV-1 RNA Qualitative Assay with 16- and 32-Member Specimen Pools , 2010, Journal of Clinical Microbiology.

[14]  Gkikas Magiorkinis,et al.  Increasing prevalence of HIV-1 subtype A in Greece: estimating epidemic history and origin. , 2007, The Journal of infectious diseases.

[15]  F. Buonaguro,et al.  Human Immunodeficiency Virus Type 1 Subtype Distribution in the Worldwide Epidemic: Pathogenetic and Therapeutic Implications , 2007, Journal of Virology.

[16]  H. Niesters,et al.  Multicenter Evaluation of the New Abbott RealTime Assays for Quantitative Detection of Human Immunodeficiency Virus Type 1 and Hepatitis C Virus RNA , 2007, Journal of Clinical Microbiology.

[17]  F. Wiesmann,et al.  Comparison of four commercial quantitative HIV-1 assays for viral load monitoring in clinical daily routine , 2007, Clinical chemistry and laboratory medicine.

[18]  A. Geretti,et al.  Comparative Evaluation of the Performance of the Abbott Real-Time Human Immunodeficiency Virus Type 1 (HIV-1) Assay for Measurement of HIV-1 Plasma Viral Load following Automated Specimen Preparation , 2006, Journal of Clinical Microbiology.

[19]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[20]  J. Kahn,et al.  Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy , 1996 .

[21]  J. Kahn,et al.  Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. , 1996, The Journal of infectious diseases.

[22]  J. Goedert,et al.  Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. , 1996, JAMA.

[23]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[24]  P. Hartigan,et al.  Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. , 1996, The New England journal of medicine.

[25]  J. Kahn,et al.  Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. , 1996, The Journal of infectious diseases.

[26]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.